VERONA PHARMA PLC - AMERICAN DEPOSITARY SHARES

Verona Pharma Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

27 фев 2025 06:00:00 Источник Nasdaq GlobeNewswire

Verona Pharma Announces March 2025 Investor Conference Participation

18 фев 2025 06:00:00 Источник Nasdaq GlobeNewswire

Verona Pharma to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Corporate Update

13 фев 2025 06:00:00 Источник Nasdaq GlobeNewswire

Verona Pharma Reports Strong Ohtuvayre™ Launch and Provides Preliminary Fourth Quarter and Full Year 2024 Financial Highlights

07 янв 2025 06:00:00 Источник Nasdaq GlobeNewswire

Verona Pharma Announces December 2024 Investor Conference Participation

19 ноя 2024 02:00:00 Источник Nasdaq GlobeNewswire

Verona Pharma to Present at Jefferies London Healthcare Conference

05 ноя 2024 02:00:00 Источник Nasdaq GlobeNewswire

Verona Pharma Reports Third Quarter 2024 Financial Results and Provides Corporate Update

04 ноя 2024 02:00:00 Источник Nasdaq GlobeNewswire

Verona Pharma to Report Third Quarter 2024 Financial Results and Provide Corporate Update

21 окт 2024 02:00:00 Источник Nasdaq GlobeNewswire

Verona Pharma to Present Six Analyses of the Phase 3 ENHANCE Studies in COPD at CHEST 2024

30 сен 2024 02:00:00 Источник Nasdaq GlobeNewswire

Verona Pharma to Present Additional Analyses of Phase 3 ENHANCE Studies in COPD at ERS International Congress 2024

05 сен 2024 02:00:00 Источник Nasdaq GlobeNewswire

Verona Pharma Reports Second Quarter 2024 Financial Results and Provides Corporate Update

08 авг 2024 02:00:00 Источник Nasdaq GlobeNewswire

Verona Pharma to Present at 44th Annual Canaccord Growth Conference

30 июл 2024 02:00:00 Источник Nasdaq GlobeNewswire

Verona Pharma to Report Second Quarter 2024 Financial Results and Provide Corporate Update

25 июл 2024 02:00:00 Источник Nasdaq GlobeNewswire

Verona Pharma Announces US FDA Approval of Ohtuvayre™ (ensifentrine)

26 июн 2024 16:57:26 Источник Nasdaq GlobeNewswire

Verona Pharma Reports First Quarter 2024 Financial Results and Provides Corporate Update

09 май 2024 07:15:00 Источник Nasdaq GlobeNewswire

Verona Pharma Announces $650 Million Strategic Financing with Oaktree and OMERS

09 май 2024 07:00:01 Источник Nasdaq GlobeNewswire

Verona Pharma to Present Additional Analyses of Positive Phase 3 ENHANCE Studies in COPD at ATS 2024

02 май 2024 02:00:00 Источник Nasdaq GlobeNewswire

Verona Pharma to Report First Quarter 2024 Financial Results and Provide Corporate Update

25 апр 2024 02:00:00 Источник Nasdaq GlobeNewswire

Andrew Fisher Joins Verona Pharma as General Counsel

04 мар 2024 02:00:00 Источник Nasdaq GlobeNewswire

Verona Pharma Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

29 фев 2024 02:00:00 Источник Nasdaq GlobeNewswire